{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:11:59Z","timestamp":1790446319011,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013304","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000}}],"reference-count":167,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013304.pub2","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T07:51:50Z","timestamp":1639727510000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia"],"prefix":"10.1002","volume":"2022","author":[{"given":"Viktoria","family":"M\u00fchlbauer","sequence":"additional","affiliation":[{"name":"DigiHealth Institute; Neu-Ulm University of Applied Sciences; Neu-Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"M\u00f6hler","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research and Health Economics, Centre for Health and Society, Medical Faculty and University Hospital D\u00fcsseldorf; Heinrich-Heine University; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin N","family":"Dichter","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases (DZNE); Witten Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sytse U","family":"Zuidema","sequence":"additional","affiliation":[{"name":"Department of General Practice and Elderly Care Medicine; University of Groningen, University Medical Center Groningen; Groningen Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"K\u00f6pke","sequence":"additional","affiliation":[{"name":"Institute of Nursing Science, Faculty of Medicine and University Hospital Cologne; University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika J","family":"Luijendijk","sequence":"additional","affiliation":[{"name":"Department of General Practice and Elderly Care Medicine; University of Groningen, University Medical Center Groningen; Groningen Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s002130050064","article-title":"Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment","volume":"148","author":"Allain","year":"2000","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1176\/jnp.9.4.591","article-title":"Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease","volume":"9","author":"Auchus","year":"1997","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"7496","key":"10.1002\/14651858.CD013304.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","article-title":"Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial","volume":"330","author":"Ballard","year":"2005","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1474-4422%2818%2930039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013304.pub2-BIB0005|cit5","first-page":"134143","article-title":"A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia","volume":"64","author":"Brodaty","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD013304.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/gps.1409","article-title":"Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial","volume":"20","author":"Brodaty","year":"2005","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013304.pub2-BIB0007|cit7","first-page":"AbstractNo289","article-title":"Risperidone in the treatment of agitation, aggression and psychosis of dementia","volume":"23","author":"Brodaty","year":"2002","journal-title":"Neurobiology of Aging"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013304.pub2-BIB0008|cit8","first-page":"S108","article-title":"Risperidone in the treatment of agitation and psychosis of dementia","volume":"13","author":"Brodaty","year":"2001","journal-title":"International Psychogeriatrics"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0009|cit9","unstructured":"Clarnette R Brodaty H Ames D Snowdon J Lee E Woodward M Psychological symptoms are improved with risperidone in patients with dementia-related psychosis Proceedings of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum (International Journal of Neuropsychopharmacology), June 23-27 2002, Montreal, Canada CNO - CN-01000034 2002 S91"},{"issue":"9","key":"10.1002\/14651858.CD013304.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/j.1532-5415.2004.52406.x","article-title":"The effect of risperidone on nursing burden associated with caring for patients with dementia","volume":"52","author":"Frank","year":"2004","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0011|cit11","unstructured":"Kirwan J Brodaty H Ames D Snowdon J Woodward M Clarnette R Risperidone in the treatment of agitation and psychosis of dementia 155th Annual Meeting of the American Psychiatric Association; 2002 may 18-23; Philadelphia, PA, USA 2002"},{"issue":"5-6","key":"10.1002\/14651858.CD013304.pub2-BIB0012|cit12","first-page":"A30","article-title":"Risperidone in the treatment of agitation adn psychosis of dementia [abstract]","volume":"33","author":"Woodward","year":"2003","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0013|cit13","unstructured":"Woodward M Brodaty H Lee E Risperidone in the treatment of agitation and psychosis of dementia: a multicentre, double-blind, placebo controlled study Proceedings of the 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva CNO - CN-00386102 2002 255"},{"issue":"8","key":"10.1002\/14651858.CD013304.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1176\/appi.ajgp.13.8.722","article-title":"Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia","volume":"13","author":"Deberdt","year":"2005","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0015|cit15","unstructured":"Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease Eli Lilly and Company Clinical Trial Registry CNO - CN-00744177 2005 1 52"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0016|cit16","unstructured":"Olanzapine versus risperidone and placebo in the treatment of psychosis and associated behavioral disturbances in patients with dementia Eili Lilly Inc CNO - CN-00548830 2005 1 38"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0017|cit17","unstructured":"Risperidone vs olanzapine vs placebo (ORP): Alzheimer's disease with psychosis John Hopkins University clinical trials database 2000"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0018|cit18","unstructured":"Deberdt WG De Deyn PP Carrasco MM Jeandel C Hay DP Feldman PD Cognitive function in patients with Alzheimer's dementia during double-blind treatment of psychosis with olanzapine Conference posterEli lilly and CO 2005"},{"issue":"2","key":"10.1002\/14651858.CD013304.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/gps.1032","article-title":"Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease","volume":"19","author":"De Deyn","year":"2004","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013304.pub2-BIB0020|cit20","first-page":"336","article-title":"Cognitive function in patients with alzheimers dementia during double-blind treatment of psychosis with olanzapine","volume":"15","author":"Hay","year":"2003","journal-title":"International Psychogeriatrics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013304.pub2-BIB0021|cit21","first-page":"337","article-title":"Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with alzheimer's dementia","volume":"15","author":"Hoffmann","year":"2003","journal-title":"International Psychogeriatrics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013304.pub2-BIB0022|cit22","first-page":"307","article-title":"Analysis of motor function in patients with Alzheimer's dementia during double-blind treatment of psychosis with olanzapine","volume":"15","author":"Kinon","year":"2003","journal-title":"International Psychogeriatrics"},{"issue":"5","key":"10.1002\/14651858.CD013304.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/01.jcp.0000178415.22309.8f","article-title":"Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study","volume":"25","author":"De Deyn","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0024|cit24","unstructured":"Michaels K Sackeim HA Marder K Mayeux RP Antipsychotics in the treatment of dementia complicated by psychosis Conference Proceedings 151st Annual Meeting of the American Psychiatric Association.; 30th May-4th June, 1998; Toronto, Ontario, Canada CNO - CN-00279937 1998 No. 27D"},{"issue":"11","key":"10.1002\/14651858.CD013304.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1176\/ajp.155.11.1512","article-title":"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease","volume":"155","author":"Devanand","year":"1998","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013304.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/gps.930100208","article-title":"A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients","volume":"10","author":"Lyons","year":"1995","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's Dementia: two12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0029|cit29","unstructured":"Aripiprazole for the treatment of patients with agitation associated with dementia of the Alzheimer's type http:\/\/www.clinicaltrials.jp\/user\/showCteDetailE.jsp?japicId=JapicCTI-142578 2015"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0030|cit30","unstructured":"Colon S Figueroa C Thein S Siegal A Arias B De La Ganadara J Efficacy and safety of a flexible dose of risperidone versus placebo in the treatment of psychosis of Alzheimer's disease Clinical trials journal CNO - CN-00404159 2002 1 6"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/01.JGP.0000194643.63245.8c","article-title":"Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial","volume":"14","author":"Mintzer","year":"2006","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD013304.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","article-title":"Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses","volume":"15","author":"Mintzer","year":"2007","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0033|cit33","unstructured":"A study of the effectiveness and safety of risperidone versus placebo in the treatment of patients with hallucinations and delusions associated with Alzheimer's disease https:\/\/clinicaltrials.gov\/show\/NCT00287742 2006"},{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/gps.1892","article-title":"Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study","volume":"23","author":"Paleacu","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0035|cit35","unstructured":"Johnson Pharmaceutical R Development LLC Efficacy and safety of a flexible dose of risperidone versus placebo in the treatment of psychosis of Alzheimers disease. A double-blind, placebo-controlled, parallel-group study Yale open data access (YODA) project 2003"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0036|cit36","unstructured":"Brecher M Clyde C Risperidone Study Group Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia Proceedings of the 8th Congress of the International Psychogeriatric Association: Jerusalem, Israel, August 17-22, 1997 CNO - CN-00713949 1997 10"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Brecher M Follow-up study of risperidone in the treatment of patients with dementia: interim results on tardive dyskinesia and dyskinesia severity 11th European College of NeuropsychoPharmacology Congress. Paris, France. 31st October - 4th November 1998 1998","DOI":"10.1016\/S0924-977X(98)80511-7"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0038|cit38","unstructured":"Grossman F Gharabawi G Elderly patients with dementia and psychosis treated with risperidone Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden CNO - CN-00385944 2002 AbstractNo299"},{"issue":"5","key":"10.1002\/14651858.CD013304.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1532-5415.2004.52230_12.x","article-title":"Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias","volume":"52","author":"Grossman","year":"2004","journal-title":"Journal of the American Geriatrics Society"},{"issue":"1-2","key":"10.1002\/14651858.CD013304.pub2-BIB0040|cit40","first-page":"145","article-title":"Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia","volume":"29","author":"Katz","year":"1998","journal-title":"Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13, Davos, Switzerland CNO - CN-00856755"},{"issue":"2","key":"10.1002\/14651858.CD013304.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial","volume":"60","author":"Katz","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD013304.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1176\/appi.ajgp.12.5.499","article-title":"Risperidone and falls in ambulatory nursing home residents with dementia and psychosis or agitation: secondary analysis of a double-blind, placebo-controlled trial","volume":"12","author":"Katz","year":"2004","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013304.pub2-BIB0043|cit43","first-page":"84","article-title":"Risperidone in the treatment of nonaggressive agitated symptoms related to dementia: analysis of 617 patients in a randomized, double-blind controlled trial","volume":"15","author":"Mintzer","year":"2003","journal-title":"International Psychogeriatrics"},{"issue":"2004","key":"10.1002\/14651858.CD013304.pub2-BIB0044|cit44","first-page":"153","article-title":"Psychosis of Alzheimer's disease: validity of the construct, and response to risperidone","volume":"9","author":"Schneider","year":"2004","journal-title":"Research and Practice in Alzheimer's Disease"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0045|cit45","unstructured":"Schneider LS Katz IR Park S Azen S Martinez RA Psychosis of alzheimer's disease: validity and response to risperidone 155th annual meeting of the American Psychiatric Association; 2002 May 18-23rd; philadelphia, PA, USA 2002"},{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00019442-200307000-00004","article-title":"Psychosis of Alzheimer disease: validity of the construct and response to risperidone","volume":"11","author":"Schneider","year":"2003","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/oxfordjournals.schbul.a006993","article-title":"Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies","volume":"29","author":"Davis","year":"2003","journal-title":"Schizophrenia Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3233\/JAD-150869","article-title":"Classification of neuropsychiatric symptoms requiring antipsychotic treatment in patients with Alzheimer's disease: analysis of the CATIE-AD study","volume":"50","author":"Nagata","year":"2016","journal-title":"Journal of Alzheimer's Disease"},{"issue":"9","key":"10.1002\/14651858.CD013304.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.4088\/JCP.17m11461","article-title":"Placebo effects in the treatment of Noncognitive symptoms of Alzheimer's disease: analysis of the CATIE-AD data","volume":"78","author":"Ozawa","year":"2017","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD013304.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1001\/archpsyc.64.11.1259","article-title":"Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease","volume":"64","author":"Rosenheck","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/oxfordjournals.schbul.a006991","article-title":"Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial","volume":"29","author":"Schneider","year":"2003","journal-title":"Schizophrenia Bulletin"},{"issue":"SUPPL. 13","key":"10.1002\/14651858.CD013304.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"A75","DOI":"10.1097\/01.JGP.0000346964.46544.ec","article-title":"Second-generation antipsychotics for Alzheimer's disease patients and metabolic abnormalities: the CATIE-AD study","volume":"17","author":"Schneider","year":"2009","journal-title":"American Journal of Geriatric Ppsychiatry"},{"issue":"15","key":"10.1002\/14651858.CD013304.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease","volume":"355","author":"Schneider","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00019442-200111000-00004","article-title":"National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology","volume":"9","author":"Schneider","year":"2001","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0055|cit55","unstructured":"Schneider LS Vigen CL Mack WJ Dagerman KS Keefe R Sano M Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease: outcomes from CATIE-AD American Journal of Geriatric Psychiatry 2009 A76 10.1097\/01.JGP.0000346964.46544.ec"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0056|cit56","unstructured":"Sultzer DL Davis SM Tariot PN Dagerman KS Lebowitz BD Lyketsos CG Antipsychotic medication treatment response in Alzheimer's disease (CATIE-AD): patient symptoms, function, and life quality, and caregiver well-being American Journal of Geriatric Psychiatry 2009 A74 A75 10.1097\/01.JGP.0000346964.46544.ec"},{"issue":"7","key":"10.1002\/14651858.CD013304.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1176\/appi.ajp.2008.07111779","article-title":"Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial","volume":"165","author":"Sultzer","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD013304.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","article-title":"Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD","volume":"168","author":"Vigen","year":"2011","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD013304.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jagp.2017.01.016","article-title":"Lack of early improvement with antipsychotics is a marker for subsequent nonresponse in behavioral and psychological symptoms of dementia: analysis of CATIE-AD Data","volume":"25","author":"Yoshida","year":"2017","journal-title":"American jJournal of GeriatricPpsychiatry"},{"issue":"5","key":"10.1002\/14651858.CD013304.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1176\/appi.ajp.2008.08081218","article-title":"Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study","volume":"166","author":"Zheng","year":"2009","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD013304.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/JGP.0b013e318165db77","article-title":"A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease","volume":"16","author":"Streim","year":"2008","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0062|cit62","unstructured":"A Protocol No 5077IL\/0039: a multicenter, double-blind comparison of efficacy and safety of Seroquel\u00ae (quetiapine fumarate), haloperidol, and placebo in the treatment of elderly subjects residing in nursing homes or assisted care facilities and presenting with Alzheimer's dementia and psychoses or other selected psychoses www.clinicalstudyresults.org 2006"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0063|cit63","unstructured":"Tariot P Schneider L Katz I Mintzer J Street J Quetiapine in nursing home residents with Alzheimer's dementia and psychosis American Journal of Geriatric Psychiatry 2002 93"},{"issue":"9","key":"10.1002\/14651858.CD013304.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/01.JGP.0000196628.12010.35","article-title":"Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial Epub 2006 Aug 11; Erratum in: am J Geriatr Psychiatry 2006 Nov;14(11): 988Tariot PN et al","volume":"14","author":"Tariot","year":"2006","journal-title":"AmericanJjournal of Geriatric Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD013304.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1212\/WNL.55.9.1271","article-title":"Treatment of agitation in AD: a randomized, placebo-controlled clinical trial","volume":"55","author":"Teri","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0066|cit66","unstructured":"A multicenter, double-blind, randomized comparison of the efficacy and safety of quetiapine fumarate (SEROQUEL\u00ae) and placebo in the treatment of agitation associated with dementia Clinicaltrials.gov [http:\/\/clinicaltrials.gov] 2009"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0067|cit67","unstructured":"[Public title] Seroquel- agitation associated with dementia; [Scientific title] A multicenter, double-blind, randomized, comparison of the efficacy and safety of quetiapine fumarate (SEROQUEL) and placebo in the treatment of agitation associated with dementia ClinicalTrials.gov [http:\/\/clinicaltrials.gov] CNO - CN-00724658 2002"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0068|cit68","unstructured":"Tariot PN Efficacy and tolerability of atypical antipsychotics in agitation and psychosis: research results 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, GA CNO - CN-00547351 2005 No. 31A"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0069|cit69","first-page":"269","article-title":"Quetiapine for the treatment of agitation in patients with dementia","volume":"abstract NR.726","author":"Zhong","year":"2005","journal-title":"158th Annual Meeting of the American Psychiatric Association, Atlanta, GA, USA, 21-26 May, 2005 CNO - CN-00548828"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/156720507779939805","article-title":"Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study","volume":"4","author":"Zhong","year":"2007","journal-title":"Current Alzheimer Research"},{"issue":"5","key":"10.1002\/14651858.CD013304.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1212\/WNL.53.5.946","article-title":"A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia","volume":"53","author":"DeDeyn","year":"1999","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD013304.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archneur.1989.00520440036018","article-title":"A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease","volume":"46","author":"Devanand","year":"1989","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/gps.1667","article-title":"Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study","volume":"22","author":"Holmes","year":"2007","journal-title":"International Journal ofGgeriatric Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013304.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/0891988704264535","article-title":"Risperidone is effective for wandering and disturbed sleep\/wake patterns in Alzheimer's disease","volume":"17","author":"Meguro","year":"2004","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0075|cit75","unstructured":"Treatment of Agitation\/Psychosis in Dementia\/Parkinsonism (TAP\/DAP) https:\/\/clinicaltrials.gov\/show\/NCT00043849 CNO - CN-01496582 2002"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","article-title":"Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients","volume":"159","author":"Pollock","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0077|cit77","first-page":"180","article-title":"Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients","volume":"7","author":"Pollock","year":"2003","journal-title":"Research and Practice in Alzheimer's Disease"},{"issue":"var.pagings","key":"10.1002\/14651858.CD013304.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/j.jns.2013.07.1110","article-title":"A randomized placebo-controlled trial of quetiapine for the treatment of behavioral and psychological symptom of dementia in Alzheimer's disease patients","volume":"Conference: 21s","author":"Shin","year":"2013","journal-title":"Journal of the Neurological Sciences"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013304.pub2-BIB0079|cit79","first-page":"115","article-title":"Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease","volume":"6","author":"Clark","year":"1999","journal-title":"European Journal of Neurology"},{"issue":"suppl 5","key":"10.1002\/14651858.CD013304.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"S332","DOI":"10.1016\/S0924-977X(99)80472-6","article-title":"Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease","volume":"9","author":"Clark","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4088\/JCP.v62n0108","article-title":"The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease","volume":"62","author":"Clark","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Clark WS Street JS Gannon KS Sanger TM Tollefson GD Breier A Reduction of psychotic symptoms in patients with lewy body like symptoms treated with olanzapine Proceedings of the 9th Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver, Canada CNO - CN-00858739 1999 172","DOI":"10.1016\/S0924-977X(99)80471-4"},{"issue":"Suppl","key":"10.1002\/14651858.CD013304.pub2-BIB0083|cit83","first-page":"S162","article-title":"Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease","volume":"47","author":"Clark","year":"1999","journal-title":"Biological Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013304.pub2-BIB0084|cit84","first-page":"S357","article-title":"Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease","volume":"3","author":"Clark","year":"2000","journal-title":"InternationalJjournal of Neuropsychopharmacology"},{"issue":"1-2 Suppl","key":"10.1002\/14651858.CD013304.pub2-BIB0085|cit85","first-page":"227","article-title":"Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease","volume":"49","author":"Feldman","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0086|cit86","unstructured":"Kennedy J Basson B Zagar A Clark W Sanger T Street J The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioral disturbances Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville CNO - CN-00368536 2000 175"},{"issue":"6","key":"10.1002\/14651858.CD013304.pub2-BIB0087|cit87","first-page":"42","article-title":"The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioural disturbances","volume":"1","author":"Kennedy","year":"2000","journal-title":"Clinical Neuropsychological Assessment"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0088|cit88","unstructured":"Kennedy JS Basson BR Zagar AJ Gilmore JA Wei H Kinon BJ The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioral disturbances: continued improvement in quality of life despite weight change during olanzapine or haloperidol treatment Proceedings of the 52nd Institute on Psychiatric Services; 2000 oct 25-29, Philadelphia 2000"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1002\/1099-1166%28200112%2916:1+%3C::AID-GPS570%3E3.0.CO","article-title":"The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease","volume":"16","author":"Kennedy J","year":"2001","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013304.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1002\/1099-1166(200112)16:1+<::AID-GPS568>3.0.CO;2-M","article-title":"Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis","volume":"16 Suppl 1","author":"Mintzer","year":"2001","journal-title":"InternationalJournal of Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0091|cit91","first-page":"5","article-title":"Is olanzapine effective in the treatment of agitation\/aggression and psychosis in patients with Alzheimer disease (AD)? [Commentary on Street JS, Clark WS, Gannon KS et al Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial Archives of General Psychiatry 2000;57: 968-76]","volume":"4","author":"Slawson","year":"2001","journal-title":"Evidence Based Practice736"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0092|cit92","first-page":"S89","article-title":"Effect of olanzapine on psychosis and behavioural disturbances associated with alzheimer's disease","volume":"47","author":"Street","year":"1999","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Street J Clark WS Gannon K Mitan S Kadam D Sanger T Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disaese Proceedings of the 9th Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver, Canada CNO - CN-00368751 1999 123","DOI":"10.1016\/S0924-977X(99)80470-2"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0094|cit94","first-page":"298","article-title":"Olanzapine in the treatment of psychosis and behavioural disturbances assocated with alzheimer's disease","volume":"1-3","author":"Street","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"suppl 5","key":"10.1002\/14651858.CD013304.pub2-BIB0095|cit95","first-page":"S331","article-title":"Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disease","volume":"9","author":"Street","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013304.pub2-BIB0096|cit96","first-page":"S57","article-title":"Olanzapine in the treatment of psychosis and behavioural disturbances associated with alzheimer's disease","volume":"187","author":"Street","year":"2001","journal-title":"Journal of Neurosurgery"},{"issue":"10","key":"10.1002\/14651858.CD013304.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial","volume":"57","author":"Street","year":"2000","journal-title":"Archives of General Psychiatry CNO - CN-00322635"},{"issue":"10","key":"10.1002\/14651858.CD013304.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group","volume":"57","author":"Street","year":"2000","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Street JS Clark WS Gannon KS Mitan S Sanger TM Tollefson GD Olanzapine in the treatment of psychosis and behavioral disturbances associated with alzheimer's disease Proceedings of the 152nd annual meeting of the American Psychiatric Association; 1999 may 15-20, Washington DC 1999","DOI":"10.1016\/S0924-977X(99)80470-2"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013304.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1002\/1099-1166(200112)16:1+<::AID-GPS569>3.0.CO;2-J","article-title":"Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia","volume":"16","author":"Street","year":"2001","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0101|cit101","first-page":"105","article-title":"Olanzapin in the treatment of psychological and behavioral diseases in patients with Alzheimer-type dementia","volume":"3","author":"Trequattrini","year":"2003","journal-title":"Giornale di Neuropsicofarmacologia"},{"issue":"5-6","key":"10.1002\/14651858.CD013304.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jpm.12464","article-title":"The health professional experience of using antipsychotic medication for dementia in care homes: a study using grounded theory and focussing on inappropriate prescribing","volume":"25","author":"Almutairi","year":"2018","journal-title":"Journal of Psychiatric and Mental Health Nursing"},{"issue":"7","key":"10.1002\/14651858.CD013304.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jalz.2016.03.006","article-title":"Mortality risk in current and new antipsychotic Alzheimer's disease users: large scale Japanese study","volume":"12","author":"Arai","year":"2016","journal-title":"Alzheimer's & Dementia"},{"issue":"7496","key":"10.1002\/14651858.CD013304.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","article-title":"Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial","volume":"330","author":"Ballard","year":"2005","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003476.pub2","article-title":"The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease","author":"Ballard","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0106|cit106","unstructured":"Banerjee S The use of antipsychotic medication for people with dementia: time for action. A report, 2010 webarchive.nationalarchives.gov.uk\/20130104175837\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_108302.pdf"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/fampra\/cmx061","article-title":"Neuropsychiatric symptoms and psychotropic drug use in patients with dementia in general practices","volume":"35","author":"Borsje","year":"2018","journal-title":"Family Practice"},{"issue":"15","key":"10.1002\/14651858.CD013304.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.297.15.1683","article-title":"Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials","volume":"297","author":"Bridge","year":"2007","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0109|cit109","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychological Bulletin"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0111|cit111","first-page":"309","article-title":"Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument","volume":"8 Suppl 3","author":"Cohen-Mansfield","year":"1996","journal-title":"International Psychogeriatrics \/ IPA"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0112|cit112","unstructured":"Covidence systematic review software Veritas Health Innovation 2013"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S1041610214001963","article-title":"Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition","volume":"27","author":"Cummings","year":"2015","journal-title":"International Psychogeriatrics \/ IPA"},{"issue":"5","key":"10.1002\/14651858.CD013304.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1212\/WNL.53.5.946","article-title":"A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia","volume":"53","author":"DeDeyn","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0115|cit115","unstructured":"European Medicines Agency Questions and answers on the review of the use of conventional antipsychotic medicines in elderly patients with dementia, 2008 www.ema.europa.eu\/en\/documents\/other\/questions-answers-review-use-conventional-antipsychotic-medicines-elderly-patients-dementia_en.pdf"},{"issue":"6","key":"10.1002\/14651858.CD013304.pub2-BIB0116|cit116","first-page":"268","article-title":"Atypicality of atypical antipsychotics","volume":"7","author":"Farah","year":"2005","journal-title":"Primary Care Companion Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD013304.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/(SICI)1099-1166(199807)13:7<433::AID-GPS798>3.0.CO;2-9","article-title":"Medication use in nursing homes for elderly people","volume":"13","author":"Furniss","year":"1998","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1176\/jnp.3.4.371","article-title":"Hallucinations and associated factors in Alzheimer's disease","volume":"3","author":"Gilley","year":"1991","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"2","key":"10.1002\/14651858.CD013304.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables \u2013 binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013304.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles \u2013 continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0121|cit121","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventionsversion 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7748\/nop2008.04.20.3.33.c6497","article-title":"Chemical restraint in nursing older people","volume":"20","author":"Hughes","year":"2008","journal-title":"Nursing Older People"},{"issue":"10","key":"10.1002\/14651858.CD013304.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jamda.2015.03.015","article-title":"The Mortality Risk of Conventional Antipsychotics in Elderly Patients: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.","volume":"16","author":"Hulshof","year":"2015","journal-title":"Journal of the American Medical Directors Association"},{"issue":"2","key":"10.1002\/14651858.CD013304.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/pds.4903","article-title":"Run-in periods and clinical outcomes of antipsychotics in dementia: A meta-epidemiological study of placebo-controlled trials","volume":"29","author":"Hulshof","year":"2020","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/jrsm.1294","article-title":"Challenges of identifying unpublished data from clinical trials: getting the best out of clinical trials registers and other novel sources.","volume":"9","author":"Isojarvi","year":"2018","journal-title":"Research Synthesis Methods"},{"issue":"11","key":"10.1002\/14651858.CD013304.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1017\/S1041610216001150","article-title":"Psychotropic drug prescriptions in Western European nursing homes","volume":"28","author":"Janus","year":"2016","journal-title":"International Psychogeriatrics \/ IPA"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1017\/S1041610216001897","article-title":"Determinants of the nurses' and nursing assistants' request for antipsychotics for people with dementia","volume":"29","author":"Janus","year":"2017","journal-title":"International Psychogeriatrics \/ IPA"},{"issue":"10","key":"10.1002\/14651858.CD013304.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1176\/appi.ajp.2007.06101710","article-title":"Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications","volume":"164","author":"Kales","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2011.11030347","article-title":"Risk of mortality among individual antipsychotics in patients with dementia","volume":"169","author":"Kales","year":"2012","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0165-0327(89)90021-9","article-title":"Onset of response in relation to outcome in depressed outpatients with placebo and imipramine","volume":"17","author":"Khan","year":"1989","journal-title":"Journal of Affective Disorders"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0131|cit131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000464","article-title":"Thioridazine for dementia","author":"Kirchner","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1532-5415.2007.01625.x","article-title":"Antipsychotic drug use and risk of pneumonia in elderly people","volume":"56","author":"Knol","year":"2008","journal-title":"Journal of the American Geriatrics Society"},{"issue":"20","key":"10.1002\/14651858.CD013304.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1001\/jama.293.20.2462","article-title":"FDA warns antipsychotic drugs may be risky for elderly","volume":"293","author":"Kuehn","year":"2005","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"103489","DOI":"10.1016\/j.ijnurstu.2019.103489.","article-title":"Comparative efficacy of non-pharmacological interventions on agitation in people with dementia: A systematic review and Bayesian network meta-analysis","volume":"102","author":"Leng","year":"2020","journal-title":"International Journal of Nursing Studies"},{"issue":"39","key":"10.1002\/14651858.CD013304.pub2-BIB0135|cit135","first-page":"1","article-title":"A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia","volume":"18","author":"Livingston","year":"2014","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"6","key":"10.1002\/14651858.CD013304.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1192\/bjp.bp.113.141119.","article-title":"Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials","volume":"205","author":"Livingston","year":"2014","journal-title":"British Journal of Psychiatry"},{"issue":"10113","key":"10.1002\/14651858.CD013304.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD013304.pub2-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002852","article-title":"Haloperidol for agitation in dementia","author":"Lonergan","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013304.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/pds.3912","article-title":"Terminal illness and the increased mortality risk of conventional antipsychotics in observational studies: a systematic review","volume":"25","author":"Luijendijk","year":"2016","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3233\/JAD-140579","article-title":"The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials","volume":"42","author":"Ma","year":"2014","journal-title":"Journal of Alzheimer's disease"},{"issue":"8","key":"10.1002\/14651858.CD013304.pub2-BIB0141|cit141","first-page":"5","article-title":"Antipsychotics: use in elderly people with dementia","volume":"2","author":"Medicines and Healthcare products Regulatory Agency","year":"2009","journal-title":"Drug Safety Update"},{"issue":"10","key":"10.1002\/14651858.CD013304.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"e007382","DOI":"10.1136\/bmjopen-2014-007382","article-title":"Monetary costs of agitation in older adults with Alzheimer's disease in the UK: prospective cohort study","volume":"5","author":"Morris","year":"2015","journal-title":"BMJ Open"},{"issue":"7","key":"10.1002\/14651858.CD013304.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.biopsych.2013.08.020","article-title":"Psychosis in Alzheimer's disease","volume":"75","author":"Murray","year":"2014","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0145|cit145","doi-asserted-by":"crossref","unstructured":"Neufeld KJ Needham DM Oh ES Wilson LM Nikooie R Zhang A Antipsychotics for the Prevention and Treatment of Delirium. Comparative Effectiveness Review No. 219. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-2015-00006-I-2.) AHRQ Publication No. 19-EHC019-EF. Rockville, MD: Agency for Healthcare Research and Quality; https:\/\/doi.org\/10.23970\/AHRQEPCCER219","DOI":"10.23970\/AHRQEPCCER219"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","article-title":"Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management","volume":"28","author":"Pierre","year":"2005","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0147|cit147","volume-title":"World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends.","author":"Prince","year":"2015"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ageing\/afx147","article-title":"Potentially inappropriate medication among people with dementia in eight European countries","volume":"47","author":"Renom-Guiteras","year":"2018","journal-title":"Age and Ageing"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0149|cit149","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2019"},{"issue":"10","key":"10.1002\/14651858.CD013304.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1001\/archneur.62.10.1601","article-title":"Delusions and hallucinations are associated with worse outcome in Alzheimer disease","volume":"62","author":"Scarmeas","year":"2005","journal-title":"Archives of Neurology"},{"issue":"21-22","key":"10.1002\/14651858.CD013304.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1111\/jocn.12066","article-title":"Distress experienced by nurses in response to the challenging behaviour of residents \u2013 evidence from German nursing homes","volume":"21","author":"Schmidt","year":"2012","journal-title":"Journal of Clinical Nursing"},{"issue":"15","key":"10.1002\/14651858.CD013304.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"issue":"15","key":"10.1002\/14651858.CD013304.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease","volume":"355","author":"Schneider","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"Art. No.: ED000","DOI":"10.1002\/14651858.ED000098","article-title":"Regulatory agencies hold the key to improving Cochrane Reviews of drugs","volume":"4","author":"Schroll","year":"2015","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0155|cit155","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020)","author":"Sch\u00fcnemann","year":"2020"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jclinepi.2018.05.004","article-title":"Efficacy of antipsychotics in dementia depended on the definition of patients and outcomes: a meta-epidemiological study","volume":"101","author":"Smeets","year":"2018","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD013304.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/2040622316658463","article-title":"Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses","volume":"7","author":"Tampi","year":"2016","journal-title":"Therapeutic Advances in Chronic Disease"},{"issue":"1","key":"10.1002\/14651858.CD013304.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4088\/JCP.09m05486oli","article-title":"The effect of staff training on agitation and use of restraint in nursing home residents with dementia: a single-blind, randomized controlled trial","volume":"71","author":"Testad","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013304.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1017\/S1041610216001654","article-title":"Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis","volume":"29","author":"Toot","year":"2017","journal-title":"International Psychogeriatrics \/ IPA"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007726.pub3","article-title":"Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia","author":"Van Leeuwen","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4, 2010","key":"10.1002\/14651858.CD013304.pub2-BIB0161|cit161","first-page":"414","article-title":"Delirium in hospitalized patients\u202f: underdiagnosed and undertreated missed opportunities in preventive care","volume":"96","author":"Wahid","year":"2004","journal-title":"Journal of the National Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000280437","article-title":"Determinants of quality of life in nursing home residents with dementia","volume":"29","author":"Wetzels","year":"2010","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD013304.pub2-BIB0163|cit163","volume-title":"ATC Classification Index with DDDs, 2018","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2017"},{"issue":"5","key":"10.1002\/14651858.CD013304.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/JCP.0000000000001083","article-title":"Mortality risk of atypical antipsychotics for behavioral and psychological symptoms of dementia: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials","volume":"39","author":"Yeh","year":"2019","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD013304.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jama.2017.11112","article-title":"Antipsychotics to treat agitation or psychosis in patients with dementia","volume":"318","author":"Yohanna","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD013304.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"e190828","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1002\/14651858.CD013304.pub2-BIB0167|cit167","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013304","article-title":"Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia","author":"M\u00fchlbauer","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T17:54:10Z","timestamp":1719683650000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013304.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":167,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013304.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]}}}